Log in

Relevant bibliographies by topics / CD30+/CD30L T cell

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'CD30+/CD30L T cell'

Author: Grafiati

Published: 11 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CD30+/CD30L T cell.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CD30+/CD30L T cell"

1

Younes, A., U. Consoli, V. Snell, et al. "CD30 ligand in lymphoma patients with CD30+ tumors." Journal of Clinical Oncology 15, no. 11 (1997): 3355–62. http://dx.doi.org/10.1200/jco.1997.15.11.3355.

Full text

Abstract:

PURPOSE CD30 ligand (CD30L), which is expressed on resting B and activated T lymphocytes, can induce cell death in several CD30+ cell lines. Patients with CD30+ tumors (Hodgkin's disease and Ki-1+ non-Hodgkin's lymphoma) frequently have elevated soluble CD30 (sCD30) levels in their serum, which correlates with a poor prognosis. The role of sCD30 in protecting tumor cells from CD30L-mediated cell death and the pattern of CD30L expression on human peripheral-blood lymphocytes (PBLs) of normal donors and patients with CD30+ tumors are investigated. MATERIALS AND METHODS CD30L surface protein expr

APA, Harvard, Vancouver, ISO, and other styles

2

Willis, Cynthia R., Yi-Ling Hu, Anh Leith, and James B. Rottman. "CD30 / CD30L interactions promote class-switched antibody responses to T-dependent antigens (34.3)." Journal of Immunology 182, no. 1_Supplement (2009): 34.3. http://dx.doi.org/10.4049/jimmunol.182.supp.34.3.

Full text

Abstract:

Abstract The cell-surface glycoproteins CD30 and CD30L are members of the TNFR and TNF superfamilies, respectively. CD30 is expressed on subpopulations of activated T and B cells. CD30L is expressed on activated T cells, macrophages, and dendritic cells, as well as germinal center B cells. CD30 / CD30L interactions provide activation-induced costimulatory signals that sustain T-cell responses, mediate B-cell activity, and generate long-lived memory T cells for chronic B-cell help. Although other activation-induced costimulatory molecules induce antibody isotype class switching, it is less clea

APA, Harvard, Vancouver, ISO, and other styles

3

Mori, M., C. Manuelli, N. Pimpinelli, et al. "CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression." Blood 94, no. 9 (1999): 3077–83. http://dx.doi.org/10.1182/blood.v94.9.3077.

Full text

Abstract:

Abstract Primary CD30+ cutaneous T-cell lymphomas (CTCLs) represent a spectrum of non-Hodgkin’s lymphomas (NHLs) that have been well defined at the clinical, histologic, and immunologic level. This group, which includes 2 main entities (large cell lymphoma and lymphomatoid papulosis [LyP]) and borderline cases, is characterized by the expression of CD30 antigen by neoplastic large cells at presentation, possible spontaneous regression of the skin lesions, and generally favorable clinical course. Although the functional relevance of CD30 and its natural ligand (CD30L) expression in most cases o

APA, Harvard, Vancouver, ISO, and other styles

4

Mori, M., C. Manuelli, N. Pimpinelli, et al. "CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression." Blood 94, no. 9 (1999): 3077–83. http://dx.doi.org/10.1182/blood.v94.9.3077.421k28_3077_3083.

Full text

Abstract:

Primary CD30+ cutaneous T-cell lymphomas (CTCLs) represent a spectrum of non-Hodgkin’s lymphomas (NHLs) that have been well defined at the clinical, histologic, and immunologic level. This group, which includes 2 main entities (large cell lymphoma and lymphomatoid papulosis [LyP]) and borderline cases, is characterized by the expression of CD30 antigen by neoplastic large cells at presentation, possible spontaneous regression of the skin lesions, and generally favorable clinical course. Although the functional relevance of CD30 and its natural ligand (CD30L) expression in most cases of NHL is

APA, Harvard, Vancouver, ISO, and other styles

5

Barbieri, Alessandro, Marzia Dolcino, Elisa Tinazzi, et al. "Characterization of CD30/CD30L+Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis." Journal of Immunology Research 2015 (2015): 1–10. http://dx.doi.org/10.1155/2015/729654.

Full text

Abstract:

The CD30/CD30L signalling system has been implicated in the pathogenesis of several autoimmune and inflammatory conditions. In rheumatoid arthritis (RA), soluble CD30 (sCD30) levels reflect the recruitment of CD30+T cells into the inflamed joints and correlate with a positive response to immunosuppressive therapy. The aim of our report was to clarify the role of CD30/CD30L signalling system in the pathogenesis of RA. Our analysis of the CD30L+T cell subsets in peripheral blood (PB) and synovial fluid (SF) of RA patients and of the related cytokine profiles suggests the involvement of CD30/CD30

APA, Harvard, Vancouver, ISO, and other styles

6

Rottman, James B., Yi-Ling Hu, and Cynthia Willis. "Blockade of the CD30/CD30L pathway inhibits renal disease in young, SLE-prone NZB/W F1 mice (50.41)." Journal of Immunology 182, no. 1_Supplement (2009): 50.41. http://dx.doi.org/10.4049/jimmunol.182.supp.50.41.

Full text

Abstract:

Abstract CD30 and CD30L are interacting members of the TNFR and TNF family, respectively. CD30 is expressed by subsets of activated T and B cells, whereas CD30L is expressed by subsets of activated T cells, macrophages and dendritic cells. The CD30 / CD30L interaction modulates T cell activation, germinal center formation and antibody isotype class switching. Given the importance of this pathway to B cell function, we tested the hypothesis that blockade of the CD30 / CD30L pathway would decrease or abrogate autoantibody formation and renal disease in the NZB/W F1 murine model of systemic lupus

APA, Harvard, Vancouver, ISO, and other styles

7

Romagnani, Paola, Francesco Annunziato, Roberto Manetti, et al. "High CD30 Ligand Expression by Epithelial Cells and Hassal's Corpuscles in the Medulla of Human Thymus." Blood 91, no. 9 (1998): 3323–32. http://dx.doi.org/10.1182/blood.v91.9.3323.

Full text

Abstract:

Abstract CD30 is a member of tumor necrosis factor (TNF) receptor superfamily that is expressed by activated T cells in the presence of interleukin-4 (IL-4). Although CD30 can mediate a variety of signals, CD30-deficient mice have impaired negative selection of T cells, suggesting that at least in the context of murine thymus, CD30 is a cell death–mediating molecule. The ligand for CD30 (CD30L) is a membrane-associated glycoprotein related to TNF, which is known to be expressed mainly by activated T cells and other leukocytes. However, the nature of CD30L-expressing cells involved in the inter

APA, Harvard, Vancouver, ISO, and other styles

8

Romagnani, Paola, Francesco Annunziato, Roberto Manetti, et al. "High CD30 Ligand Expression by Epithelial Cells and Hassal's Corpuscles in the Medulla of Human Thymus." Blood 91, no. 9 (1998): 3323–32. http://dx.doi.org/10.1182/blood.v91.9.3323.3323_3323_3332.

Full text

Abstract:

CD30 is a member of tumor necrosis factor (TNF) receptor superfamily that is expressed by activated T cells in the presence of interleukin-4 (IL-4). Although CD30 can mediate a variety of signals, CD30-deficient mice have impaired negative selection of T cells, suggesting that at least in the context of murine thymus, CD30 is a cell death–mediating molecule. The ligand for CD30 (CD30L) is a membrane-associated glycoprotein related to TNF, which is known to be expressed mainly by activated T cells and other leukocytes. However, the nature of CD30L-expressing cells involved in the interaction wi

APA, Harvard, Vancouver, ISO, and other styles

9

Gattei, Valter, Massimo Degan, Annunziata Gloghini, et al. "CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin." Blood 89, no. 6 (1997): 2048–59. http://dx.doi.org/10.1182/blood.v89.6.2048.

Full text

Abstract:

Abstract CD30 ligand (CD30L) is a type-II membrane glycoprotein capable of transducing signals leading to either cell death or proliferation through its specific counterstructure CD30. Although several lines of evidence indicate that CD30L plays a key role as a paracrine- or autocrine-acting surface molecule in the deregulated cytokine cascade of Hodgkin's disease, little is known regarding its distribution and biologic significance in other human hematopoietic malignancies. By analyzing tumor cells from 181 patients with RNA studies and immunostaining by the anti-CD30L monoclonal antibody M80

APA, Harvard, Vancouver, ISO, and other styles

10

Wiley, S. R., R. G. Goodwin, and C. A. Smith. "Reverse signaling via CD30 ligand." Journal of Immunology 157, no. 8 (1996): 3635–39. http://dx.doi.org/10.4049/jimmunol.157.8.3635.

Full text

Abstract:

Abstract CD30 ligand (CD30L), a member of the TNF family, is a type II membrane protein with a C-terminal extracellular domain that is homologous with the extracellular domains of other TNF family members. Also, like most TNF family members, the N-terminal cytoplasmic domain of CD30L is conserved across species, but not between family members, suggesting a possible biological function. Motivated by this observation, we investigated the potential for CD30L, when activated by cross-linking, to directly transduce a signal to the ligand-bearing cell. Cross-linking of CD30L by a mAb or by CD30-Fc f

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "CD30+/CD30L T cell"

1

Hirano, Ayumi. "T dependent B cell help in cattle : immunoregulatory function of interleukin-4 and CD40-CD40L interactions /." free to MU campus, to others for purchase, 1997. http://wwwlib.umi.com/cr/mo/fullcit?p9841150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Schubert, Lisa Ann. "Characterization of the transcriptional regulation of the human CD40L gene in CD4 T cells /." Thesis, Connect to this title online; UW restricted, 1998. http://hdl.handle.net/1773/8325.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fischer, Marie. "Mast cells in Hodgkin lymphoma : or 'What's a nice cell like you doing in a tumour like this?'." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.bibl. [distributör], 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4620.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

BARBIERI, Alessandro. "ROLE OF CD30/CD30L POSITIVE T CELLS IN THE PATHOGENESIS OF RHEUMATOID ARTHRITIS." Doctoral thesis, 2014. http://hdl.handle.net/11562/710761.

Full text

Abstract:

CD30 e CD30 ligando (CD30L) fanno parte, rispettivamente, della superfamiglia dei recettori del TNF e del TNF. Il numero di cellule T CD30+ T risulta elevato in molte patologie e l’interazione tra cellule T CD30+ e CD30L+ può portare sia alla proliferazione cellulare che all’apoptosi. Nei pazienti affetti da artrite reumatoide (AR), i livelli della molecola solubile del CD30 (sCD30) sembrano correlare il reclutamento di linfociti T CD30+ nelle articolazioni infiammate ed elevati livelli circolanti sono associati ad una buona risposta a terapie immunosoppressive di tipo sia classico che biotecn

APA, Harvard, Vancouver, ISO, and other styles

5

Harlin, Helena. "TRAF4 and CD30/TRAF2 in normal T cell function /." 2001. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&res_dat=xri:pqdiss&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&rft_dat=xri:pqdiss:3019923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Boyle, Julia Katrina. "The role of CD30 in the regulation of T cell function." Thesis, 2003. http://hdl.handle.net/2429/14546.

Full text

Abstract:

CD30 is a member of the TNFR superfamily that was initially identified on Reed-Sternberg cells of Hodgkin's disease and is widely expressed in other lymphomas as well as in a number of autoimmune diseases. On normal cells, CD30 is expressed primarily on activated CD8⁺ T cells and is induced by two distinct pathways, an IL-4 dependent pathway and an IL-4-independent pathway via CD28. The precise role of CD30 has been controversial, but it has been implicated in a number of T cell functions, including costimulation, cytokine production, cell survival and cytotoxicity, although much of the publis

APA, Harvard, Vancouver, ISO, and other styles

7

Chen, Jui-Chieh, and 陳瑞傑. "The inhibition of T cell proliferation by CD30 expression on the Hodgkin’s cancer cell." Thesis, 2003. http://ndltd.ncl.edu.tw/handle/49838763617401022976.

Full text

Abstract:

碩士<br>國立臺灣大學<br>生物化學暨分子生物學研究所<br>91<br>英文摘要 Hodgkin''s disease is a type of malignant lymphoma, characterized by the presence of abnormal cells, named Reed-Sternberg cells, in patient’s lymph nodes. CD30 was originally described as a marker of Hodgkin/Reed-Sternberg cells. CD30 and its cognate ligand, CD153, belong to members of the TNFR and TNF superfamilies, respectively. CD30 is expressed on the surface of Hodgkin/Reed-Sternberg (H-RS) cell lines (KM-H2), while expression of CD153 can be induced on the surface of peripheral blood T cells by anti-CD3 or PHA activation. In this st

APA, Harvard, Vancouver, ISO, and other styles

8

Snell, Laura Margaret Lucette. "The Role of TNFR Family Members GITR and CD30 on CD8 T Cell Responses." Thesis, 2012. http://hdl.handle.net/1807/36299.

Full text

Abstract:

GITR and CD30 are T cell costimulatory members of the TNFR superfamily known to regulate T cell responses. Elucidating the mechanisms whereby these receptors modulate T cell responses is crucial for maximizing their potential for immunotherapy. In this thesis, I examine the role of GITR and CD30 on CD8 T cell responses to influenza virus. I show that CD8 T cell intrinsic GITR is required for both maximal primary and secondary CD8 T cell expansion to influenza, while in contrast, CD30 is dispensable for anti-influenza CD8 T cell responses. GITR does not impact on CD8 T cell proliferation or hom

APA, Harvard, Vancouver, ISO, and other styles

9

"THE CRITICAL ROLE OF CD4+ TH CELLS IN CD8+ CTL RESPONSES AND ANTI-TUMOR IMMUNITY." Thesis, 2012. http://hdl.handle.net/10388/ETD-2012-04-424.

Full text

Abstract:

The goal of this body of research was to elucidate the mechanism by which CD4+ T cells provide help for CD8+ cytotoxic T lymphocyte (CTL) responses in different immunization types. The establishment of diseases, such as chronic infections and cancers, is attributed to severe loss of or dysfunctions of CD4+ T cells. Even in acute infections, CD4+ T cell deficiency leads to poor memory responses. While the role of CD4+ T cells is being increasingly appreciated in these diseases, the timing and nature of CD4+ T help and associated molecular mechanisms are not completely understood. Growing eviden

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "CD30+/CD30L T cell"

1

Kadin, Marshall E., and Francine Foss. "Primary Cutaneous and Systemic CD30+ T-cell Lymphoproliferative Disorders." In T-Cell Lymphomas. Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-170-7_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kaudewitz, Peter, Iannis Anagnostopoulos, Michael Hummel, and Harald Stein. "HTLV-1 Proviral Sequences in Cutaneous CD30-Positive T Large Cell Lymphomas." In Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin. Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-1861-7_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kazlouskaya, V., J. Ho, and O. E. Akilov. "Case 42. Primary cutaneous CD30 T-cell posttransplant lymphoproliferative disorder with δ expression." In Cutaneous Lymphomas. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-59129-8_42.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wood, G. S., J. W. Gould, and A. C. Gilliam. "Primary cutaneous CD30+ large-cell lymphoma with natural killer-cell phenotype and the t(2;5) translocation." In Cutaneous Lymphomas. Steinkopff, 2001. http://dx.doi.org/10.1007/978-3-642-57624-9_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Strauchen, James A. "Peripheral T Cell and NK Cell Neoplasms: Ill. Anaplastic Large Cell Lymphomas." In Diagnostic Histopathology of the Lymph Node. Oxford University PressNew York, NY, 1998. http://dx.doi.org/10.1093/oso/9780195118605.003.0021.

Full text

Abstract:

Abstract The anaplastic large cell lymphomas include anaplastic large cell lymphoma (CD30 +) of T and null cell types, primary cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma, Hodgkin’s-like. Anaplastic large cell lymphomas of B cell type are considered with the diffuse large B cell lymphomas in Chapter 18.

APA, Harvard, Vancouver, ISO, and other styles

6

"CD30+ cutaneous large T-cell lymphoma." In Dermatology Therapy. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/3-540-29668-9_525.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Armitage, R. J. "CD40 Ligand (CD40L)." In Guidebook to Cytokines and Their Receptors. Oxford University PressOxford, 1995. http://dx.doi.org/10.1093/oso/9780198599470.003.0028.

Full text

Abstract:

Abstract CD40 is a 50 kDa type I glycoprotein which is a member of the TNF receptor (TNFR) family. This group of related molecules includes both p60 and p80 forms of TNFR, the T cell activation antigens OX40, 4-1BB, CD27 and CD30, Fas antigen and a Shope fibroma virus-encoded TNFR homologue (Mallett and Barclay 1991). CD40 is expressed on B cells, follicular dendritic cells, thymic epithelium, mast cells, monocytes and some carcinomas (Clark 1990; Galy and Spits 1992; Alderson et al. 1993). Monoclonal antibodies (mAb) specific for CD40 induce a range of biological activities on human B cells i

APA, Harvard, Vancouver, ISO, and other styles

8

Strauchen, James A. "Hodgkin’s Disease: II. Classical Hodgkin’s Disease." In Diagnostic Histopathology of the Lymph Node. Oxford University PressNew York, NY, 1998. http://dx.doi.org/10.1093/oso/9780195118605.003.0023.

Full text

Abstract:

Abstract Classical Hodgkin’s Disease (HD) is characterized by proliferation of Reed-Sternberg (RS) and Reed-Sternberg-variant cells in an inflammatory background. Although several histopathologic variants are recognized, the RS and RS-variant cells demonstrate a uniform immunophenotype, characterized by CD15 and CD30 positivity and lack of specific B or T cell antigens.

APA, Harvard, Vancouver, ISO, and other styles

9

"Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders." In Hematopathology. Elsevier, 2013. http://dx.doi.org/10.1016/b978-1-4377-1758-7.00082-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kadin, Marshall E. "Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders." In Hematopathology. Elsevier, 2011. http://dx.doi.org/10.1016/b978-0-7216-0040-6.00039-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "CD30+/CD30L T cell"

1

Rana, Seema, and Rajiv Tangri. "Anaplastic large cell lymphoma ALK negative vs. peripheral T cell lymphoma (NOS) - diagnostic dilemma." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685354.

Full text

Abstract:

Middle aged female presented with generalised lymphadenopathy and fever for last one month. Peripheral blood findings were within normal limits. There was no extra nodal involvement. FNAC performed initially from a cervical node suggested possibility of Hodgkin’s lymphoma and a whole node biopsy was performed. Histopathogical examination revealed effaced nodal architecture and a polymorphous population of lymphocytes, plasma cells, neutrophils and scattered large mononuclear cells with prominent nucleolus. An initial panel of CD3, CD20, LCA, CD15, CD30 and PAX5 was performed. The large atypica

APA, Harvard, Vancouver, ISO, and other styles

2

Wu, Yang, Dan Chen, Rong Ma, et al. "Abstract 1444: The new therapy strategy for treatment of peripheral T cell lymphomas: CD30-targeted CAR-modified T cell therapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1444.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Wu, Yang, Dan Chen, Rong Ma, et al. "Abstract 1444: The new therapy strategy for treatment of peripheral T cell lymphomas: CD30-targeted CAR-modified T cell therapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1444.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Caires, Elisana Maria Santos, Régis Resende Paulinelli, Miliana Tostes Lucatto, Eneida Ribeiro Marinho, and Henrique Moura de Paula. "BREAST IMPLANT–ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL): A CASE REPORT WITH ATYPICAL SYMPTOMS." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2096.

Full text

Abstract:

The BIA-ALCL is a rare type of T-cell lymphoma CD30+ e AKL−, occurring more common in women with Allergantextured implants. It presents most frequently as a late-onset accumulation of seroma fluid between the implant and less frequently as a palpable tumor mass, with malignant cells infiltrating through the capsule and surrounding tissue with potential lymph node and systemic involvement. This article describes a case report of a 65-year-old female patient with BIA-ALCL complaining of erythema in her right breast for almost 7 months. She agreed no family history of cancer and no fever. The pat

APA, Harvard, Vancouver, ISO, and other styles

5

Escribà-Garcia, Laura, Carmen Alvarez-Fernández, Ana Carolina Caballero, et al. "Abstract A028: Memory stem T-cells expressing an optimized CD30-specific chimeric antigen receptor (CAR) efficiently eradicate peripheral T-cell lymphoma in vivo." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-a028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Cho, Hyun-Il, Chung-Hyo Kang, Sang-Eun Lee, et al. "250 Chimeric antigen receptors containing CD30-derived costimulatory domain elicit augmented T cell effector functions and anti-tumor efficacy." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0250.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Heiser, Ryan A., Bryan M. Grogan, Luke S. Manlove, and Shyra J. Gardai. "Abstract 1789: CD30+T regulatory cells, but not CD30+CD8 T cells, are impaired following brentuximab vedotin treatment in vitro and in vivo." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1789.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kua, Lindsay, Chee Hoe Ng, Jin Wei Tan, et al. "240 Humanized CD30 chimeric antigen receptor T cells with a novel 4–1BB derived spacer have improved activity and safety against CD30-positive lymphomas." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0240.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

O’Connor, Brian P., Bryan M. Grogan, Reice D. James, et al. "1155 Activated regulatory T cells in solid tumors express CD30, which are selectively targeted by the novel anti-CD30 antibody drug conjugate SGN-35T." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.1155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Merz, Christian, Jaromir Sykora, Viola Marschall, et al. "Abstract 1760: The hexavalent CD40 agonist HERA-CD40L augments multi-level crosstalk between T cells and antigen-presenting cells." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1760.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!